Pathophysioloy and treatment of painful diabetic neuropathy

Mitra Tavakoli; Moaz Mojaddidi; Hassan Fadavi; Rayaz A. Malik

doi:10.1007/s11916-008-0034-1

Pathophysioloy and treatment of painful diabetic neuropathy

Mitra Tavakoli, Moaz Mojaddidi, Hassan Fadavi, Rayaz A. Malik

Research output: Contribution to journal › Article › peer-review

Abstract

Diabetes is the most common cause of peripheral neuropathy, and painful diabetic neuropathy (PDN) affects approximately 30% of diabetic patients with neuropathy. It is extremely distressing for the patient and poses significant management difficulties because no treatment provides total relief, and side effects of therapy are a major limiting factor for titrating therapy. Understanding the pathogenesis of diabetic neuropathy may lead to the development of new treatments to prevent nerve damage, and a better understanding of the mechanisms that modulate pain may lead to more effective relief of painful symptoms. We provide an update on the pathogenesis, diagnosis, and treatment of PDN. Copyright © 2008 by Current Medicine Group LLC.

Original language	English
Pages (from-to)	192-197
Number of pages	5
Journal	Current Pain and Headache Reports
Volume	12
Issue number	3
DOIs	https://doi.org/10.1007/s11916-008-0034-1
Publication status	Published - Jun 2008

Keywords

Animals
genetics: Diabetes Complications
genetics: Diabetic Neuropathies
Genetic Predisposition to Disease
Humans

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11916-008-0034-1

Cite this

@article{421816c5a3b640d884d3b21e2c48efdb,

title = "Pathophysioloy and treatment of painful diabetic neuropathy",

abstract = "Diabetes is the most common cause of peripheral neuropathy, and painful diabetic neuropathy (PDN) affects approximately 30% of diabetic patients with neuropathy. It is extremely distressing for the patient and poses significant management difficulties because no treatment provides total relief, and side effects of therapy are a major limiting factor for titrating therapy. Understanding the pathogenesis of diabetic neuropathy may lead to the development of new treatments to prevent nerve damage, and a better understanding of the mechanisms that modulate pain may lead to more effective relief of painful symptoms. We provide an update on the pathogenesis, diagnosis, and treatment of PDN. Copyright {\textcopyright} 2008 by Current Medicine Group LLC.",

keywords = "Animals, genetics: Diabetes Complications, genetics: Diabetic Neuropathies, Genetic Predisposition to Disease, Humans",

author = "Mitra Tavakoli and Moaz Mojaddidi and Hassan Fadavi and Malik, {Rayaz A.}",

year = "2008",

month = jun,

doi = "10.1007/s11916-008-0034-1",

language = "English",

volume = "12",

pages = "192--197",

journal = "Current Pain and Headache Reports",

issn = "1531-3433",

publisher = "Current Science, Inc",

number = "3",

}

TY - JOUR

T1 - Pathophysioloy and treatment of painful diabetic neuropathy

AU - Tavakoli, Mitra

AU - Mojaddidi, Moaz

AU - Fadavi, Hassan

AU - Malik, Rayaz A.

PY - 2008/6

Y1 - 2008/6

N2 - Diabetes is the most common cause of peripheral neuropathy, and painful diabetic neuropathy (PDN) affects approximately 30% of diabetic patients with neuropathy. It is extremely distressing for the patient and poses significant management difficulties because no treatment provides total relief, and side effects of therapy are a major limiting factor for titrating therapy. Understanding the pathogenesis of diabetic neuropathy may lead to the development of new treatments to prevent nerve damage, and a better understanding of the mechanisms that modulate pain may lead to more effective relief of painful symptoms. We provide an update on the pathogenesis, diagnosis, and treatment of PDN. Copyright © 2008 by Current Medicine Group LLC.

AB - Diabetes is the most common cause of peripheral neuropathy, and painful diabetic neuropathy (PDN) affects approximately 30% of diabetic patients with neuropathy. It is extremely distressing for the patient and poses significant management difficulties because no treatment provides total relief, and side effects of therapy are a major limiting factor for titrating therapy. Understanding the pathogenesis of diabetic neuropathy may lead to the development of new treatments to prevent nerve damage, and a better understanding of the mechanisms that modulate pain may lead to more effective relief of painful symptoms. We provide an update on the pathogenesis, diagnosis, and treatment of PDN. Copyright © 2008 by Current Medicine Group LLC.

KW - Animals

KW - genetics: Diabetes Complications

KW - genetics: Diabetic Neuropathies

KW - Genetic Predisposition to Disease

KW - Humans

U2 - 10.1007/s11916-008-0034-1

DO - 10.1007/s11916-008-0034-1

M3 - Article

C2 - 18796269

SN - 1531-3433

VL - 12

SP - 192

EP - 197

JO - Current Pain and Headache Reports

JF - Current Pain and Headache Reports

IS - 3

ER -

Pathophysioloy and treatment of painful diabetic neuropathy

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this